{"data":{"trials":{"globalActiveTrials":21174,"byDisease":[{"id":"hematology","label":"Bleeding Disorders","activeTrials":157},{"id":"endocrinology","label":"Type 1 Diabetes","activeTrials":404},{"id":"cardiology","label":"Heart Disease","activeTrials":2496},{"id":"pulmonology","label":"Lung Disease","activeTrials":234},{"id":"oncology","label":"Cancer","activeTrials":5870},{"id":"ophthalmology","label":"Vision / Blindness","activeTrials":211},{"id":"obesity","label":"Obesity & Metabolic","activeTrials":1018},{"id":"hepatology","label":"Liver Disease","activeTrials":1540},{"id":"neurology","label":"Neurodegenerative Disease","activeTrials":675},{"id":"gastroenterology","label":"Inflammatory Bowel Disease","activeTrials":772},{"id":"nephrology","label":"Chronic Kidney Disease","activeTrials":469},{"id":"rheumatology","label":"Autoimmune & Rheumatic Disease","activeTrials":587},{"id":"dermatology","label":"Skin & Genetic Skin Disease","activeTrials":253},{"id":"psychiatry","label":"Psychiatric & Mood Disorders","activeTrials":758},{"id":"geromedicine","label":"Aging & Precision Geromedicine","activeTrials":707}],"source":"ClinicalTrials.gov","_freshness":{"stale":false,"available":true,"partial":false,"computedAt":"2026-07-31T12:44:46.136Z","note":"Live from ClinicalTrials.gov."},"message":"Right now, 21,174 clinical trials are running to cure human disease. The window is still open."},"research":{"count":5,"source":"The Last Economy Wire cure-research index","newestPublishedAt":"2026-07-31T00:00:00.000Z","pagination":{"limit":5,"offset":0,"total":675,"returned":5,"hasMore":true,"nextCursor":"bzo1","nextOffset":5},"articles":[{"title":"EC Approves Rinvoq as First Systemic Vitiligo Drug","url":"https://novapharmanews.com/eu/news/ec-approves-rinvoq-upadacitinib-non-segmental-vitiligo","source":"novapharmanews.com","publishedAt":"2026-07-31T00:00:00.000Z","domain":"dermatology","significance":"The European Commission has approved AbbVie’s upadacitinib (Rinvoq) as the first systemic treatment for non-segmental vitiligo, following Phase 3 Viti-Up results showing statistically meaningful total-body and facial repigmentation at week 48 in adults and adolescents eligible for systemic therapy. More broadly, this is another step in the shift from managing visible autoimmune damage to engineering disease reversal: AI-driven target discovery and trial design are increasingly turning complex immune skin disease into a tractable intervention problem, an example of intelligence inversion as the bottleneck moves from biology to computation and execution."},{"title":"Early life sugar rationing and ageing related diseases, biological ageing and mortality | Nature Communications","url":"https://www.nature.com/articles/s41467-026-76257-1","source":"www.nature.com","publishedAt":"2026-07-31T00:00:00.000Z","domain":"geromedicine","significance":"Researchers analyzing 64,809 UK Biobank participants found that exposure to Britain’s postwar sugar rationing during the first 1,000 days of life was associated with lower later-life incidence of ageing-related disease and a 19% reduction in all-cause mortality, with mediation evidence linking much of the survival benefit to slower biological ageing. The result underscores the larger AI-era shift toward treating disease as an engineering problem: once large-scale longitudinal data can resolve how early-life exposures alter ageing trajectories, intelligence inversion becomes possible—moving from guessing causes to identifying the controllable levers that shape lifelong health."},{"title":"Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod - BioSpace","url":"https://www.biospace.com/press-releases/abivax-announces-positive-pre-nda-interaction-with-the-fda-for-obefazimod","source":"www.biospace.com","publishedAt":"2026-07-31T00:00:00.000Z","domain":"gastroenterology","significance":"Abivax said it had a positive pre-NDA interaction with the FDA for obefazimod, its anti-inflammatory candidate for moderately to severely active ulcerative colitis, and remains on track to submit its first NDA by the end of 2026. In the larger AI-for-disease frame, this is a reminder that the bottleneck is increasingly not only discovering molecules but engineering the full development and regulatory stack; the intelligence inversion comes when machine learning makes disease biology legible enough to treat as a systems problem, enabling a phase transition from empirical trial-and-error toward programmable intervention."},{"title":"FDA Licenses Ezplaz, First U.S. Freeze-Dried Plasma","url":"https://novapharmanews.com/us/news/fda-licenses-ezplaz-first-freeze-dried-plasma-us","source":"novapharmanews.com","publishedAt":"2026-07-31T00:00:00.000Z","domain":"hematology","significance":"The FDA licensed Ezplaz Freeze Dried Plasma from Vascular Solutions/Teleflex, the first U.S. freeze-dried plasma product for adult transfusion when conventional plasma is unavailable. In the broader AI-and-disease frame, this is not a model breakthrough but an infrastructure breakthrough: disease care advances when biology is converted into an engineering problem—stabilizing a labile blood product to extend access, compress logistics, and reduce time-to-treatment, the kind of system-level optimization intelligence can accelerate across medicine."},{"title":"New Antibiotic Discovered! How AI Unlocked a Hidden Gene Cluster to Fight Superbugs (2026)","url":"https://matrixshopzz.com/article/new-antibiotic-discovered-how-ai-unlocked-a-hidden-gene-cluster-to-fight-superbugs","source":"matrixshopzz.com","publishedAt":"2026-07-31T00:00:00.000Z","domain":"AMR","significance":"Researchers reporting in Nature Communications introduced DiscERN, an AI genome-mining tool that identified a previously hidden gene cluster encoding a new antibiotic active against superbugs. The result matters because it shows how machine learning can invert the discovery process: instead of waiting for nature to reveal molecules by trial and error, AI can treat antimicrobial discovery as an engineering search problem across microbial genomes. In The Last Economy frame, this is a small but real phase transition toward disease control as an information problem, where intelligence is used to find therapeutically useful biology faster than resistance can outpace it."}]},"stats":{"totalWireSignals":1463,"totalCureResearch":675,"diseaseFrontiers":15,"languages":20}},"meta":{"api":"The Last Economy Wire - Hope Signal API","version":"1.0","schemaVersion":"2","correlationId":"req_cjFHEWH2BtOg","generatedAt":"2026-07-31T12:44:46.146Z","documentation":"https://negativeresistance.com/embed","license":"Free for any use. Attribution appreciated."},"notModified":false,"etag":"W/\"0645e8bb206e44ef742b368c2e71953d7a91891c\""}